Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28688933 | 0.87 | SMN1; SMN2 (0.54) | LMNAHTTKDM4EPOLBTSHR | |
| SCHEMBL1549799 | 0.85 | ESR1 (0.61) | KDM4ETSHRCYP1A2CYP2C9HIF1A | |
| SCHEMBL18780376 | 0.85 | LMNA (0.51) | LMNAHTTKDM4EPOLBCYP1A2 | |
| SCHEMBL28827968 | 0.85 | HPGD (0.62) | LMNAHTTKDM4EPOLBHPGD | |
| SCHEMBL197583 | 0.83 | PPARD (0.55) | — | |
| SCHEMBL13659584 | 0.83 | AR (0.46) | LMNAPOLBTSHRCYP1A2CYP2C9 | |
| SCHEMBL3016429 | 0.83 | VDR (0.47) | LMNAKDM4EPOLBTSHRCYP1A2 | |
| SCHEMBL3003324 | 0.83 | ESR1 (0.62) | KDM4EPOLBTSHRCYP1A2CYP2C9 | |
| SCHEMBL959829 | 0.82 | HTT (0.52) | LMNAHTTKDM4EPOLBTSHR | |
| SCHEMBL656844 | 0.82 | HTT (0.49) | LMNAHTTKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118322102-A | Preparation method of efficient disc repairing device of plane grinding machine | 江苏富乐华功率半导体研究院有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118322102-A | Preparation method of efficient disc repairing device of plane grinding machine | 江苏富乐华功率半导体研究院有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230416210-A1 | METHODS OF MAKING A PPAR-DELTA AGONIST | RENEO PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4251144-A1 | METHODS OF MAKING A PPAR-DELTA AGONIST | Reneo Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116761596-A | Methods of making PPAR-delta agonists | 雷内奥制药公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2022115326-A1 | METHODS OF MAKING A PPAR-DELTA AGONIST | RENEO PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115326-A1 | METHODS OF MAKING A PPAR-DELTA AGONIST | RENEO PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1438283-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20030109579-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2003-06-12 | — | — | US | disclosed |
| WO-2003033453-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109579-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | LMNA 1974/4885HTT 3193/4885KDM4E 3030/4885 |
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | LMNA 1393/4885HTT 2775/4885KDM4E 4443/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | LMNA 2274/4885HTT 1519/4885KDM4E 843/4885 |
| US-20230416210-A1 | METHODS OF MAKING A PPAR-DELTA AGONIST | PPARA, PPARG, PPARD | LMNA 1438/4885HTT 3742/4885KDM4E 2659/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | LMNA 3168/4885HTT 1592/4885KDM4E 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.